Table 3. The relation between clinical characteristics of B-ALL patients and ex vivo cytotoxicity of DS/Cu in primary samples.
| Characteristic | DS(μM) | 0 | 0 | 0.025 | 0.05 | 0.10 | 0.20 | P- value |
|---|---|---|---|---|---|---|---|---|
| Cu(μM) | 0 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | ||
| Age, years | ≥35(n=11) | 37.36± 17.91 | 38.11± 18.53 | 45.47± 19.96 | 57.43± 23.71 | 65± 23.59 | 72.81± 20.61 | |
| <35(n=21) | 37.35± 17.49 | 39.68± 19.81 | 42.71± 17.26 | 57.62± 22.31 | 69.88± 18.09 | 74.44± 17.06 | 0.744 | |
| WBC(x109/L) | ≥30(n=22) | 40.04± 19.37 | 41.96± 20.28 | 48.88± 18.27 | 62.57± 21.65 | 69.26± 21.59 | 73.88± 19.09 | |
| <30(n=10) | 32.82± 11.31 | 35.48± 14.53 | 39.55± 16.84 | 51.46± 24.1 | 61.88± 22.32 | 69.09± 18.83 | 0.044* | |
| LDH | High(n=22) | 38.80± 18.95 | 40.52± 19.92 | 44.67± 22.28 | 55.83± 25.61 | 64.37± 23.25 | 71.77± 20.82 | |
| Normal(n=10) | 34.61± 15.85 | 36.13± 17.63 | 48.62± 14.92 | 62.6± 16.43 | 71.96± 18.04 | 76.02± 15.26 | 0.644 | |
| Status of d14 | CR(n=20) | 37.17± 17.7 | 38.91± 18.66 | 45.97± 18.15 | 56.3± 23.19 | 63.92± 20.85 | 71.80± 17.4 | |
| NR(n=12) | 36.7± 19.76 | 38.41± 21.32 | 42.71± 21.97 | 57.39± 25.91 | 69.62± 23.23 | 74.32± 21.83 | 0.577 | |
| Status after induction therapy | CR(n=25) | 40.42± 17.46 | 39.88± 17.98 | 46.83± 17.52 | 59.63± 22.7 | 67.43± 20.67 | 73.94± 18.35 | |
| NR(n=7) | 33.86± 21.82 | 35.95± 24.92 | 38.55± 24.63 | 50.6± 25.48 | 63.76± 28.04 | 69.52± 23.8 | 0.106 | |
| Extramedullary infiltration | yes(n=24) | 37.42± 16.94 | 38.89± 17.84 | 42.24± 18.73 | 55.95± 21.15 | 65.73± 22.72 | 73.42± 20.39 | |
| No(n=8) | 37.7± 21.79 | 39.91± 23.69 | 54.41± 17.26 | 63.89± 15.05 | 69.78± 19.68 | 72.13± 15.78 | 0.542 | |
| Immune phenotype | Pro-B(n=13) | 36.35± 19.94 | 37.46± 20.5 | 45.34± 17.69 | 62.97± 17.7 | 71.11± 16.46 | 75.58± 13.25 | |
| Non-proB(n=19) | 38.28± 16.86 | 40.30± 18.49 | 45.24± 20.12 | 54.49± 26.04 | 63.75± 24.73 | 71.4± 22.46 | 0.484 | |
| Risk category | High(n=13) | 39.25± 19.75 | 42.03± 20.95 | 45.21± 19.13 | 58.6± 19.06 | 69.34± 18.59 | 75.11± 17.13 | |
| Standard(n=19) | 36.29± 16.96 | 37.17± 17.97 | 45.32± 19.22 | 57.44± 26.05 | 65.08± 23.75 | 71.28± 22.03 | 0.341 | |
| Ph chromosome | Positive(n=11) | 41.18± 20.94 | 44.19± 21.86 | 44.53± 19.95 | 55.84± 19.27 | 66.39± 18.74 | 72.48± 17.39 | |
| Negative(n=21) | 35.56± 16.3 | 36.51± 17.4 | 45.67± 18.77 | 59.03± 25.23 | 66.93± 23.63 | 73.44± 20.39 | 0.994 | |
| p16 gene deletion | Positive(n=12) | 41.41± 15.02 | 45.39± 17.63 | 48.56± 17.34 | 61.28± 24.65 | 67.27± 26.21 | 73.71± 22.52 | |
| Negative(n=16) | 30.09± 16.49 | 30.37± 16.57 | 38.08± 18.07 | 52.57± 23.43 | 65.06± 20.38 | 72.04± 18.69 | 0.008** |
Primary B-ALL cells were exposed to the indicated concentrations of DS with or without Cu for 24hr, after which percentage of apoptotic cells were determined by flow cytometry. Values represent mean± SD of at least three independent experiments. *P<0.05, **P<0.01.